Overview

A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind, placebo-controlled multi-center study to examine the efficacy and safety of ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc